Sun Pharma Advanced Research Company Limited (NSE:SPARC)

Market Cap	68.83B +50.8%
Revenue (ttm)	391.50M -45.4%
Net Income	15.53B
EPS	47.86
Shares Out	324.52M
PE Ratio	4.43
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,302,252
Open	213.21
Previous Close	212.11
Day's Range	195.45 - 215.37
52-Week Range	108.00 - 248.75
Beta	0.35
Analysts	n/a
Price Target	n/a
Earnings Date	May 18, 2026

About NSE:SPARC

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoria...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2006
• Employees: 316
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: SPARC